Trial
NCT06115512
A Phase 3 Study of AGA111 in Patients With Degenerative Disc Disease Undergoing Lumbar Interbody Fusion
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Angitia Biopharmaceuticals
Collaborators
—
Condition
Degenerative Disc Disease
Intervention
AGA111
Why stopped
Sponsor's strategic decision not related to safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-29